The results of the above-mentioned study encouraged other researchers to look closer at the changes in the expression of Bcl-xL protein in various types of cancers, and the aforementioned lymphoma and leukemia cell lines CL-1 and GL-1 became a model for in vitro development of new cancer therapies based on the induction of apoptosis in tumor-transformed canine cells. The gene discussed is BCL2L1; the disease is lymphoma.